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Aristolochic acid nephropathy—a progressive form of renal inter-
stitial  fibrosis—was  first  reported  in  a  group  of  young  Belgian 
patients with end-stage renal disease in 1993 and was thought to 
be caused by the use of Chinese herbal medicines that contained 
aristolochic acid (1–3). Aristolochic acid has been shown to be as-
sociated with urothelial cancer in studies of clinical cases around 
the world, in animal models, and by the detection of aristolochic 
acid–DNA adducts in kidney and ureteral tissues (4–6). In 2002, 
the International Agency for Research on Cancer classified herbal 
remedies that contain plant species of the genus Aristolochia, which 
contain a high level of aristolochic acid, as carcinogenic in humans 
(ie, group 1 carcinogens) (7). Consequently, many countries have 
since  banned  the  use  of  herbs  containing  aristolochic  acid,  in-
cluding Taiwan, in November of 2003 (8–10). Before this time, 
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random sample of the entire insured population from January 1, 1997, to December 31, 2002 (control 
subjects), were selected from the National Health Insurance reimbursement database. Subjects who were 
ever prescribed more than 500 pills of nonsteroidal anti-inflammatory drugs and/or acetaminophen were 
excluded, leaving 4594 case patients and 174 701 control subjects in the final analysis. Adjusted odds 
ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multivariable logistic regression 
models for the association between prescribed Chinese herbs containing aristolochic acid and the occur-
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disease was endemic (an indicator of chronic arsenic exposure from drinking water [a risk factor for uri-
nary tract cancer]), and history of chronic urinary tract infection. Statistical tests were two-sided.
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1.3 to 3.4; aristolochic acid: at 151–250 mg, OR = 1.4, 95% CI = 1.1 to 1.8, and at >500 mg, OR = 2.0, 95% 
CI = 1.4 to 2.9). A statistically significant linear dose–response relationship was observed between the 
prescribed dose of Mu Tong or the estimated cumulative dose of aristolochic acid and the risk of urinary 
tract cancer (P < .001 for both).
  Conclusions  Consumption of aristolochic acid–containing Chinese herbal products is associated with an increased risk 
of cancer of the urinary tract in a dose-dependent manner that is independent of arsenic exposure.
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however, products containing these herbs were widely prescribed 
in Taiwan.
In Taiwan, there have been case reports of renal failure associ-
ated with the use of Chinese herbal products (11,12) and herbs that 
contain aristolochic acid (13). However, to our knowledge, there 
have been no reports of urinary tract cancer associated with the use 
of herbs or herbal products containing aristolochic acid. In March 
of 1995, Taiwan established the National Health Insurance (NHI) 
program,  which  covers  more  than  96%  of  Taiwanese  residents 
(14). The NHI routinely reimburses enrollees for the cost of pre-
scribed medicines, including Chinese herbal products containing 
aristolochic acid, which were widely prescribed before the ban in 
2003. We used the NHI reimbursement database to conduct a 
population-based  case–control  study  to  examine  the  association 180   Articles | JNCI  Vol. 102, Issue 3  |  February 3, 2010
between  having  been  prescribed  Chinese  herbal  products  that 
contain substantial amounts of aristolochic acid, including Guan 
Mu Tong and Guang Fangchi, and the risk of urinary tract cancer. 
In addition to smoking, chronic exposure to arsenic in drinking 
water, which causes an endemic peripheral vascular disease called 
black  foot  disease  in  specific  areas  of  Taiwan,  has  been  docu-
mented to be associated with an increased incidence of bladder 
cancer (15–17). We conducted this case–control study in Taiwan 
to  examine  the  association  between  urinary  tract  cancers  and 
having been prescribed Chinese herbal products that contain aris-
tolochic acid and a potential dose–response relationship. In partic-
ular, we controlled for the potential confounding effect of arsenic 
exposure.
Materials and Methods
Study Population and Data Collection
This study was initiated after approval by the review board of the 
Committee on Chinese Medicine and Pharmacy, Department of 
Health,  Taiwan.  It  was  designed  as  a  population-based  case– 
control  study  to  investigate  associations  between  having  been 
prescribed Chinese herbal products and the occurrence of urinary 
tract cancer in Taiwan between January 1, 2001, and December 
31, 2002. All data were obtained from the NHI reimbursement 
database. The National Health Research Institutes of Taiwan (in 
Chunan,  Taiwan)  anonymized  and  maintained  the  NHI  reim-
cONteXt AND cAVeAtS
Prior knowledge
Consumption of Chinese herbs that contain aristolochic acid has 
been associated with an increased risk of urinary tract cancer.
Study design
A population-based case–control study in Taiwan to examine the 
association between prescribed Chinese herbal products that con-
tain aristolochic acid and urinary tract cancer. The analysis con-
trolled for chronic arsenic exposure in drinking water (a risk factor 
for urinary tract cancer).
Contribution
Prescribed  aristolochic  acid–containing  Chinese  herbal  products 
were associated with an increased risk of urinary tract cancer in a 
dose–dependent  manner  that  was  independent  of  arsenic 
exposure.
Implications
Products that contain any amount of aristolochic acid may carry 
substantial risk for urinary tract cancer, and continued surveillance 
of herbs or Chinese herbal products that might be adulterated with 
aristolochic acid–containing herbs is recommended.
Limitations
Not all of the diagnoses were confirmed by histopathology reports. 
Subjects may have taken additional nephrotoxic herbs or agents 
that were not prescribed. Actual intakes of the prescribed herbal 
products recorded in the database were not validated. Smoking 
history was not taken into account.
From the Editors
 
bursement data as files suitable for research (18). The identifica-
tion numbers of all individuals with reimbursement data in the 
NHI database were encrypted to protect the privacy of the individ-
uals. These files provided detailed demographic data (including 
birth date and sex) and information regarding health-care services 
provided for each patient, including all payments for outpatient 
visits,  hospitalizations,  and  prescriptions,  as  well  as  where  each 
patient lived. The data for each outpatient visit or hospitalization 
contained up to five diagnoses that were coded according to the 
International  Classification  of  Diseases,  Ninth  Revision ( ICD-9) 
classification (19), all drugs prescribed and the doses (ie, conven-
tional  medicines,  including  generic  and  commercial  brands  of 
acetaminophen [paracetamol] and nonsteroidal anti-inflammatory 
drugs, as well as Chinese herbal products), and the date of each 
prescription. During the study period (ie, from January 1, 1997, to 
December  31,  2002),  all  prescribed  medications  were  covered 
under the NHI of Taiwan and no drug could be dispensed at a 
pharmacy without a doctor’s prescription.
To select potential case subjects for this study, we first obtained 
the NHI catastrophic illness registry files for all patients who were 
diagnosed with urinary tract cancer or end-stage renal disease from 
January 1, 1997, to December 31, 2002. Because all patients who are 
registered as having a catastrophic illness are exempt from all copay-
ments, their data are very comprehensive. A diagnosis of urinary tract 
cancer or end-stage renal disease made by doctors and officials of the 
NHI is usually accurate: Urinary tract cancer must be proven by 
tissue pathology and is classified as cancer of the upper urinary tract, 
which includes the renal pelvis and ureter (ICD-9 codes 189.1 and 
189.2, respectively) or bladder cancer (ICD-9 code 188). The data-
base contained 20 777 prevalent cases of urinary tract cancer that 
were diagnosed from January 1, 1997, to December 31, 2002. Within 
this population, we identified 5995 patients who were newly diag-
nosed with urinary tract cancer from January 1, 2001, to December 
31, 2002, to allow at least 4 years between January 1, 1997, and the 
date of diagnosis to give sufficient time for case subjects to accumu-
late sufficient doses of herbal products to induce urinary tract cancer. 
The average incidence rate of urinary tract cancer for these newly 
diagnosed patients was 105 per million person-years.
The  control  group  consisted  of  a  200 000-person  random 
sample of the entire insured population in Taiwan (approximately 
22.5 million persons) from January 1, 1997, to December 31, 2002, 
and was representative of the insured population in terms of sex 
and age (18). We excluded control subjects with incomplete data 
for age or sex (n = 152) and those with any diagnosis related to 
urinary tract cancer (n = 145).
Most epidemiological studies have found the analgesic phenac-
etin  to  be  a  risk  factor  for  urinary  tract  cancer  (20),  whereas   
the available evidence for acetaminophen and nonsteroidal anti- 
inflammatory drugs (NSAIDs) as risk factors for urinary tract cancer 
are inconclusive and discrepant (21,22). Phenacetin was banned by 
the Department of Health of Taiwan in 1986 and has not been 
prescribed ever since. Because the use of 600–1000 pills of acet-
aminophen, NSAIDs, or mixed analgesics has been associated with 
an increased risk of renal damage or renal cancer in previous studies 
(23,24), to prevent confounding of our results by analgesic use, we 
excluded subjects who were ever prescribed more than a total of 
500 pills of acetaminophen and/or NSAIDs (1401 case subjects and jnci.oxfordjournals.org    JNCI | Articles 181
25 002 control subjects), which left 4594 new urinary tract cancer 
case subjects and 174 701 control subjects in the final analysis.
Exposure Assessment
According  to  standard  prescriptions  recommended  by  the 
Committee on Chinese Medicine and Pharmacy in Taiwan (25), 
Chinese herbal products produced before new regulations were 
promulgated in November of 2003 might include the following 
herbs  containing  aristolochic  acid:  Ma  Dou  Ling  (Fructus 
Aristolochiae), Tian Xian Teng (Caulis Aristolochiae), Xi Xin (Asarum 
heterotropoides), Guan Mu Tong (Aristolochia manshuriensis), Guang 
Fangchi  (Aristolochia  fangchi),  and  Qing  Mu  Xiang  (Radix 
Aristolochiae). Of these, Guan Mu Tong and Guang Fangchi were 
once  sold  under  the  names  of  Mu  Tong  (Akebia  species)  and 
Fangchi (Stephania species), respectively. Several studies revealed 
that  89.2%–100%  of  Fangchi  preparations  contained  Guang 
Fangchi (26–28), and more than 84% of Mu Tong preparations 
contained Guan Mu Tong (29). These herbs were taken as single 
products or were components of mixed herbal formulas that are 
recommended by ancient Chinese medicine books (eg, Mu Tong 
in the Long Dan Xie Gan mixture). Because the prescription data 
from the NHI database can be linked directly to the actual drug(s) 
prescribed by means of the product number, we were able to iden-
tify all subjects who had taken these Chinese herbal products. In 
addition, each pharmaceutical company in Taiwan has published 
and submitted the detailed composition of each of its products to 
the  Committee  on  Chinese  Medicine  and  Pharmacy  to  be  ap-
proved for registration. By using this information, we determined 
the  original  amounts  of  herbs,  in  grams,  for  each  mixture  of 
Chinese herbal products, and the total dose of each aristolochic 
acid–containing herb (eg, Mu Tong, Fangchi, and Xi Xin) during 
the exposure period from January 1, 1997, to the date of diagnosis 
of urinary tract cancer or December 31, 2002, if censored, was 
summed for each subject included in this study. To allow a min-
imal induction time for an exposed subject to develop urinary tract 
cancer, we calculated the cumulative dose for each herb prescribed 
to an individual up to 1 year before the diagnosis of urinary tract 
cancer. We also calculated the estimated cumulative dose of aris-
tolochic  acid  for  each  subject  using  the  following  estimates 
obtained in previous studies: The estimated average doses of aris-
tolochic acid per 1 g of Guan Mu Tong, Guang Fangchi, and Xi 
Xin were 2.59, 2.04, and 0.042 mg, respectively (26,28–31).
The reimbursement database also listed the townships in which 
all  subjects  lived.  We  identified  subjects  who  lived  in  the  four 
townships in Taiwan that have been reported to be areas endemic 
for black foot disease—Pu-Tai and Yi-Chu in Chiayi County and 
Hsueh-Chia and Pei-Men in Tainan County (16,17)—and con-
trolled for this factor as a surrogate for arsenic exposure. Because 
aristolochic  acid  is  also  associated  with  end-stage  renal  disease 
(1,2), we also linked the files of patients with urinary tract cancer 
to the catastrophic illness registry for end-stage renal disease to 
determine if there were overlapping case subjects with exposures 
to aristolochic acid and arsenic.
According  to  the  Committee  on  Chinese  Medicine  and 
Pharmacy (25), Mu Tong is usually prescribed for the treatment of 
hepatitis, urinary tract infection, rhinitis, dysmenorrhea, and ec-
zema. Recurrent or chronic urinary tract infection associated with 
schistosomiasis or prolonged indwelling catheters in patients with 
spinal cord injury is associated with an increased risk of bladder 
cancer (15,32), whereas urinary tract infection from other causes 
has not shown a consistent association with risk of bladder cancer 
(15,33). Hence, we defined patients with chronic urinary tract in-
fection as those who had such a diagnosis at least 12 times up to 1 
year before the diagnosis of urinary tract cancer, and we controlled 
for this potential confounder during the risk-estimate analysis.
Statistical Analyses
We used univariate and multivariable logistic regression models to 
assess the independent association of various risk factors with new 
occurrences  of  urinary  tract  cancer  in  case  patients  and  control 
subjects.  Potential  risk  factors  included  age,  sex,  residence  in  a 
township where black foot disease was endemic, history of chronic 
urinary tract infection, and cumulative doses of prescribed afore-
mentioned Chinese herbs containing aristolochic acid before the 
diagnosis of urinary tract cancer. For each potential risk factor, the 
odds  ratio  (OR)  for  the  occurrence  of  urinary  tract  cancer  and   
the 95% confidence interval (CI) were estimated. We constructed 
two logistic regression models for two different types of exposure 
assessment:  prescribed  dosages  of  Chinese  herbs  (model  1)  and 
different  estimated  dosages  of  aristolochic  acid  as  risk  factors 
(model 2). A Mantel extension test for linear trend was conducted 
by the Mantel–Haenszel method for the adjusted odds ratios of 
developing urinary tract cancer under different prescribed doses of 
Mu Tong, Fangchi, and Xi Xin for model 1 and by estimated doses 
of aristolochic acid for model 2. On the basis of our previous study 
on prescribed Chinese herbal products and chronic kidney disease 
(34), we initially classified the doses of Mu Tong, Fangchi, and Xi 
Xin by increments of 1, 30, 60, 100, and 200 g. Then, we combined 
several categories together to simplify the table according to the 
tendency  of  increased  risk.  We  also  tried  to  directly  apply  the 
number of grams of Mu Tong or milligrams of aristolochic acid as 
a continuous variable to fit the model and presented the increased 
risks in 30-g increments of doses of Mu Tong or 100-mg incre-
ments of aristolochic acid. x
2 tests for category variables (sex, having 
end-stage renal disease history) and t tests for continuous variables 
(age) were used to compare differences in clinical features among 
urinary tract cancer patients who consumed more than 60 g of Mu 
Tong and among urinary tract cancer patients who lived in a town-
ship where black foot disease was endemic. All the above analyses 
were conducted using the SAS statistical software (version 9.2; SAS 
Institute Inc, Cary, NC). All statistical tests were two-sided.
results
In  logistic  regression  model  1,  factors  that  were  independently 
associated with an increased risk for a new occurrence of urinary 
tract cancer after adjustment for other risk factors were being male 
(OR = 1.7, 95% CI = 1.6 to 1.8), older age, residence in a township 
where black foot disease was endemic (OR = 4.4, 95% CI = 3.4 to 
5.8), having history of chronic urinary tract infection (OR = 1.6, 
95% CI = 1.3 to 2.1), and having been prescribed more than 60 g 
of Mu Tong (for 61–100 g, OR = 1.6, 95% CI = 1.3 to 2.1; for 
101–200 g, OR = 2.0, 95% CI = 1.4 to 2.7; for >200 g, OR = 2.1, 
95% CI = 1.3 to 3.4) (Table 1). In logistic regression model 2, we 182   Articles | JNCI  Vol. 102, Issue 3  |  February 3, 2010
replaced the variables of prescribed Chinese herbs with estimated 
doses of aristolochic acid and found that estimated aristolochic acid 
doses greater than 150 mg were independently associated with an 
increased risk for occurrence of urinary tract cancer after adjustment 
for all other risk factors (for 151–250 mg, OR = 1.4, 95% CI = 1.1 
to 1.8; for 251–500 mg, OR = 1.6, 95% CI = 1.2 to 2.1; for >500 mg, 
OR = 2.0, 95% CI = 1.4 to 2.9). A statistically significant (P < .001) 
linear dose–response relationship was present between the risk of 
developing urinary tract cancer and the prescribed dose of Mu Tong 
and the estimated intake of aristolochic acid. There was also a linear 
dose–response trend when we applied the exposure variable as a 
continuous  variable  for  every  30-g  increment  of  prescribed  Mu 
Tong or 100-mg increment of estimated aristolochic acid (Table 1), 
and there was no statistically significant interaction between resi-
dence  in  a  township  where  black  foot  disease  was  endemic  and 
having  been  prescribed  aristolochic  acid–containing  herbs.  More 
than 100 g of Fangchi (OR = 3.1, 95% CI = 2.1 to 4.5) or more than 
300 g of Xi Xin (OR = 2.4, 95% CI = 1.6 to 3.8) was statistically 
significantly associated with an increased crude odds ratio for uri-
nary tract cancer. However, the adjusted odds ratios were not statis-
tically significant for subjects who were prescribed high cumulative 
doses of Fangchi or Xi Xin. The numbers of prescriptions for Ma 
Dou Ling, Tian Xian Teng, or Qing Mu Xiang were very small, and 
none of these herbs was statistically significantly associated with the 
risk of urinary tract cancer (data not shown).
The case patients were further stratified into two subgroups: 
those diagnosed with cancer of the upper urinary tract (43%; n = 
1985) and those diagnosed with bladder cancer (57%; n = 2609). In 
a multivariable logistic regression model adjusted for age and sex, 
there was a statistically significant association between residing in 
a township where black foot disease was endemic or having been 
prescribed more than 60 g of Mu Tong and an increased risk for 
the occurrence of bladder cancer (Table 2). There was a statisti-
cally  significant  (P  <  .001)  linear  dose–response  relationship 
between having been prescribed more than 60 g of Mu Tong or 
estimated consumption of more than 150 g of aristolochic acid and 
risk of occurrence of bladder cancer.
We next examined the clinical features of urinary tract cancer 
case subjects who were prescribed more than 60 g of Mu Tong 
(n = 118) or who lived in a township where black foot disease was 
endemic (n = 88) (Table 3). In general, urinary tract cancer case sub-
jects who were prescribed more than 60 g of Mu Tong were younger, 
had a higher male to female ratio, and more often experienced end-
stage renal disease before the occurrence of urinary tract cancer than 
those who lived in a township where black foot disease was endemic. 
In fact, none of the case subjects who lived in a township where black 
foot disease was endemic had end-stage renal disease before the 
occurrence of urinary tract cancer. The fact that only two case 
subjects with urinary tract cancer (one with upper urinary tract 
cancer and one with bladder cancer) lived in a township endemic 
for black foot disease and were ever prescribed more than 60 g of 
Mu Tong indicates that these two risk factors are independent.
Discussion
This population-based study is the first study to our knowledge to 
document a linear dose–response relationship between prescribed 
Chinese herbal products containing aristolochic acid and the risk 
of urinary tract cancer after controlling for confounding by age, 
sex, living in a township endemic for black foot disease (a surrogate 
of  arsenic  contamination  in  the  water  supply),  and  history  of 
chronic  urinary  tract  infection.  This  study  has  a  number  of 
strengths that deserve attention. Because the NHI reimbursement 
database collects all prescription information prospectively, we can 
rule out the possibility of recall bias for the intake doses of various 
Chinese herbal products. Because we included all patients newly 
diagnosed with urinary tract cancer in Taiwan from 1997 to 2002, 
and because the control subjects in this study were selected from a 
simple random sampling of the insured general population, we can 
also rule out the possibility of selection bias. In fact, our estimate 
of 105 new urinary tract cancer cases per million person-years in 
this study is practically the same as the 106 cases per million person-
years calculated from 2001 data of the Taiwanese National Cancer 
Registry (35). Because the Belgian patients who were diagnosed 
with urinary tract cancer after using aristolochic acid–containing 
Fangchi for an average of 15 months and 9 months after stopping 
the use of Fangchi (4,5), we allowed a minimum induction time of 
1 year and calculated the cumulative dose up to 1 year before diag-
nosis. Thus, this study design allowed us to detect most, if not all, 
cases of aristolochic acid–associated urinary tract cancer. Moreover, 
to  prevent  potential  confounding  of  our  results  by  analgesic   
nephropathy, we excluded case and control subjects with more than 
a moderate consumption (ie, 500 pills) of analgesics. Finally, we 
categorized subjects according to their residence in townships en-
demic for black foot disease (a surrogate of high arsenic exposure), 
and, by controlling for the potential confounding effects of this risk 
factor in multivariable logistic regression models, we were able to 
clearly separate the carcinogenic effect of arsenic exposure from 
that of exposure to Chinese herbal products. We further demon-
strated that distinctive clinical features are associated with exposure 
to arsenic and Chinese herbal products, indicating no confounding 
effect  of  each  on  the  other.  Thus,  we  concluded  that  a  dose– 
response  relationship  exists  between  aristolochic  acid–associated 
Chinese herbal products and urinary tract cancer.
Black foot disease is a peripheral vascular disease that has been 
endemic to the coastal region of Taiwan for the past 60 years, is 
related to the water derived from artesian wells containing arsenic, 
and has been documented to be associated with an increased inci-
dence of bladder cancer (16,17). Our multivariable logistic regres-
sion models corroborated the fact that living in a township where 
black foot disease was endemic was independently associated with 
an increased risk of cancer of the bladder and upper urinary tract. 
In addition, comparison of clinical features of patients with these 
cancers indicated that no patients with urinary tract cancer associ-
ated with black foot disease (or arsenic exposure) developed end-
stage renal disease before the occurrence of cancer. In fact, there 
were only two cases of urinary tract cancer who were simulta-
neously associated with having been prescribed more than 60 g of 
Mu Tong and with living in a township endemic for black foot 
disease. Hence, these findings indicate that exposure to more than 
60 g of Mu Tong and to arsenic are two independent risk factors 
for urinary tract cancer.
In this study, the association between the cumulative doses   
of aristolochic acid–containing herbs and the risk of occurrence jnci.oxfordjournals.org    JNCI | Articles 183
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of urinary tract cancer seemed to be dose-dependent. According 
to the annual reports of National Laboratory of Food and Drug in 
Taiwan, 1 g of Guan Mu Tong and Guang Fangchi was estimated 
to  contain  2.59  and  2.04  mg  of  aristolochic  acid,  respectively 
(26,28,29). Thus, a cumulative dose of 60 g of Mu Tong and of 
100 g of Fangchi in Chinese herbal products contains approxi-
mately 155 and 204 mg, respectively, of aristolochic acid, which is 
slightly higher than the 147-mg aristolochic acid dose reported in 
the Belgian reports (2,4). In this study, we observed a consistent 
dose–response relationship between the estimated intake of aristo-
lochic acid (or prescribed dose of aristolochic acid–containing Mu 
Tong) and urinary tract cancer, which suggests that aristolochic 
acid  may  be  the  agent  responsible  for  carcinogenicity.  In  this 
study, more than 100 g of Fangchi was statistically significantly 
associated with an increased crude odds ratio for urinary tract 
cancer; however, the association did not reach statistical signifi-
cance after adjustment for other risk factors, probably because of 
the small number of case subjects. By contrast, Xi Xin contains 
only  minute  amounts  of  aristolochic  acid,  or  approximately 
0.009–0.042 mg aristolochic acid per g, which is approximately 
1:50  to  1:200  of  the  amount  in  Aristolochia  fangchi  (30,31).  At   
the prescribed median daily dose of 0.9 g for Xi Xin in this study 
(34), exposure to more than 155 mg of aristolochic acid would 
take longer than 10 years. Thus, we were unable to detect any 
Table 2. Adjusted odds ratios (OR) for the development of upper urinary tract cancer and bladder cancer by multivariable logistic  
regression models*
Variable
Upper UTC Bladder cancer
n = 1985
Adjusted OR  
(95% CI) P n = 2609
Adjusted OR  
(95% CI) P
Residence in township endemic for  
    black foot disease
  No 1953 1.0 (Referent)   2553 1.0 (Referent)
  Yes 32 3.8 (2.6 to 5.6) <.001 56 5.0 (3.6 to 6.9) <.001
Chronic UTI
  No 1965 1.0 (Referent)   2546 1.0 (Referent)
  Yes 20 0.9 (0.6 to 1.4) .585 63 2.3 (1.7 to 3.0) <.001
Mu-Tong, total amount prescribed, g
 0 1698 1.0 (Referent)   2289 1.0 (Referent)
  1–60 239 1.1 (0.9 to 1.3) .244 250 1.0 (0.8 to 1.2) .762
  61–100 22 1.5 (0.9 to 2.3) .084 28 1.7 (1.1 to 2.6) .011
  101–200 19 1.8 (1.1 to 2.9) .026 27 2.2 (1.4 to 3.4) <.001
  > 200 7 1.3 (0.6 to 3.0) .530 15 2.8 (1.6 to 5.1) <.001
Fangchi, total amount prescribed, g
 0 1684 1.0 (Referent)   2243 1.0 (Referent)
  1–60 282 0.9 (0.8 to 1.0) .093 341 1.0 (0.8 to 1.1) .610
  61–100 6 0.6 (0.3 to 1.4) .250 9 0.7 (0.4 to 1.5) .394
  >100 13 1.3 (0.7 to 2.4) .350 16 1.3 (0.8 to 2.3) .306
Xi-Xin, total amount prescribed, g
 0 1556 1.0 (Referent)   2124 1.0 (Referent)
  1–100 391 1.1 (1.0 to 1.3) .087 448 1.1 (0.96 to 1.2) .211
  101–300 27 1.0 (0.6 to 1.5) .859 27 0.7 (0.5 to 1.1) .173
  >300 11 1.8 (0.9 to 3.5) .099 10 0.9 (0.4 to 1.8) .706
*  ORs adjusted for age, sex, residence in a township where black foot disease was endemic, and history of chronic UTI. CI = confidence interval; UTC = urinary 
tract cancer; UTI = urinary tract infection.
Table 3. Clinical features of patients with urinary tract cancer who were prescribed more than 60 g of Mu Tong or lived in an area 
endemic for black foot disease*
Feature
Upper UTC Bladder cancer
Prescribed >60 g of  
Mu Tong (n = 48)
Resident of black  
foot disease–endemic  
area (n = 32) P
Prescribed >60 g of  
Mu Tong (n = 70)
Resident of black  
foot disease–endemic  
area (n = 56) P
Mean age, y (SD) 60.6 (12.3) 66.2 (10.3) .303† 63.4 (11.9) 69.5 (9.5) .098†
Male to female ratio 1.1 0.8 .430‡ 1.5 1.4 .889‡
ESRD before UTC occurrence, % 6.3 0 .213‡ 17.1 0 .001‡
Resident of black foot  
  disease–endemic area, %
2.1 100 NA 1.4 100 NA
Prescribed >60 g of Mu Tong, % 100 3.1 NA 100 1.8 NA
*  ESRD = end-stage renal disease; NA = not applicable; UTC = urinary tract cancer.
†  Two-sided t test.
‡  Two-sided x
2 test.jnci.oxfordjournals.org    JNCI | Articles 185
association between prescription of Chinese herbal products con-
taining Xi Xin (Asarum heterotropoides) and urinary tract cancer. 
However, careful attention should still be paid regarding the use 
of  Chinese  herbal  products  containing  Xi  Xin,  and  long-term 
follow-up should be provided for subjects who regularly consume 
these products.
In  this  study,  43%  of  urinary  tract  cancer  cases  were  upper 
urinary  tract  cancer,  which  is  similar  to  rates  reported  by  the 
National Cancer Registry (35) and in a previous clinical report of 
pathology-confirmed  urinary  tract  cancer  cases  in  Taiwan  (36). 
These  rates  are  much  higher  than  those  in  other  countries,  in 
which less than 10% of all urinary tract cancer cases are upper 
urinary tract cancer (37). In this study, prescription of Chinese 
herbal  products  was  associated  with  urothelial  cancers  that  oc-
curred in all parts of the urinary tract, similar to what was reported 
in a recent case series of Belgian women who received kidney trans-
plants for end-stage aristolochic acid nephropathy in which 44.7% 
had upper urinary tract cancer and 39.5% had bladder cancer (38). 
Thus, we suggest that aristolochic acid induces urothelial cancers 
in the upper urinary tract and bladder with approximately equal 
tendency.
There are some limitations to this study. First, because patient 
identities were not available from the NHI reimbursement data-
base,  we  were  unable  to  obtain  any  histopathology  reports  to 
confirm the diagnoses. However, because the approval for regis-
tering urinary tract cancer as a catastrophic illness is based on pa-
thology and/or cytology evidence and is followed by a full waiver 
of copayment, such a diagnosis is made only after very serious 
consideration and is always accurate. The accuracy of diagnosis of 
urinary tract cancer from the NHI data is corroborated by the high 
agreement between the calculated incidence rate from this study 
and that from the National Cancer Registry of Taiwan, in which 
95%  of  bladder  cancers  and  91%–92%  of  upper  urinary  tract   
cancers have histopathologic proof (35). Second, we were unable 
to contact the patients directly about their use of herbs because of 
anonymization of their identification numbers; therefore, we could 
not rule out that subjects might have taken additional nephrotoxic 
herbs or agents that were not prescribed. However, because the 
NHI system has comprehensive coverage and the copayment for 
prescriptions is universally 50 NT$ (new Taiwan) (approximately 
equal to US $1.5), which is generally less than the cost of herbs 
sold in Taiwan’s markets, the likelihood that subjects purchased 
other  aristolochic  acid–containing  herbs,  nephrotoxic  drugs,  or 
alternative medicines without a prescription is low. Third, we were 
unable to validate the actual intake of the prescribed herbal prod-
ucts  recorded  in  the  database.  Because  95%  of  the  dosing 
frequencies for Chinese herbal products were only for 1 week (39), 
a large cumulative dose indicates that the patient continued re-
ceiving the same prescription for a long period of time and implies 
that  the  patient  actually  consumed  the  prescribed  medication. 
Even if the patient did not take all of the prescribed medications, 
our findings would underestimate the effect of aristolochic acid– 
related Chinese herbal products. Fourth, because the reimburse-
ment data did not include smoking history, we were unable to 
control  for  this  factor  in  the  model  construction.  Because  the 
smoking  rates  for  men  and  women  in  Taiwan  in  the  last  two 
decades ranged from 47% to 62% and from 2.3% to 5.3%, respec-
tively, (40), we assumed that sex was, in part, a surrogate variable 
for smoking.
In conclusion, having been prescribed more than 60 g of Mu 
Tong  or  more  than  150  mg  aristolochic  acid  from  Chinese 
herbal products was associated with an increased risk of devel-
oping urinary tract cancer. The linear dose–response relation-
ship between the estimated level of aristolochic acid and urinary 
tract cancer might be useful for considering a complete ban, or 
for establishing limits, on the consumption of herbal products 
and/or herbs that contain low amounts of aristolochic acid (41). 
Care must still be taken for prescribing doses less than 60 g of 
Mu Tong or 150 mg of aristolochic acid because there might be 
no threshold dose under a linear dose–response relationship and 
given recent evidence for an increased risk of chronic kidney 
disease associated with a prescribed dose of 30–60 g of Mu Tong 
(34). In this study, from 2001 to 2002, there were 118 new cases 
of urinary tract cancer in Taiwan associated with the ingestion 
of more than 60 g of the Chinese herb Mu Tong, which repre-
sents 3% of all new patients with urinary tract cancer. In addi-
tion to a ban on products that contain any amount of aristolochic 
acid,  we  also  recommend  continued  surveillance  of  herbs  or 
Chinese herbal products that might be adulterated with aristo-
lochic acid–containing herbs. Finally, patients with a history of 
aristolochic acid nephropathy or consumption of Mu Tong or 
Fangchi before they were banned should be monitored regularly 
for urinary cancer.
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